Holen Sie sich die Stockscreener-App
141.11
0.13%
-0.18
Handel nachbörslich:
141.12
0.010
+0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$141.29
Offen:
$141.415
24-Stunden-Volumen:
7.16M
Relative Volume:
1.01
Marktkapitalisierung:
$175.18B
Einnahmen:
$29.45B
Nettoeinkommen (Verlust:
$8.51B
KGV:
20.81
EPS:
6.7823
Netto-Cashflow:
$9.46B
1W Leistung:
-2.82%
1M Leistung:
-6.62%
6M Leistung:
+23.68%
1J Leistung:
+31.25%
1-Tages-Spanne:
$140.12
$142.09
1-Wochen-Bereich:
$139.23
$148.22
52-Wochen-Spanne:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
141.11 | 175.40B | 29.45B | 8.51B | 9.46B | 6.7823 |
|
LLY
Lilly Eli Co
|
917.50 | 819.81B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
237.60 | 571.52B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
206.23 | 368.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
188.93 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
148.19 | 285.86B | 54.72B | 14.02B | 15.32B | 7.1855 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock - Yahoo Finance Singapore
Gilead Sciences, Inc. $GILD Shares Bought by Swiss Life Asset Management Ltd - MarketBeat
Investment Research Partners LLC Takes $928,000 Position in Gilead Sciences, Inc. $GILD - MarketBeat
Coldstream Capital Management Inc. Acquires 8,807 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance Australia
Ciara Is Bringing Back the Pop Culture PSA (Exclusive) - Cosmopolitan
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Gilead Sciences initiates challenging study for aggressive breast cancer form - Traders Union
Antiretroviral Therapy Market Critical Analysis with Expert Opinion| Gilead Sciences, Viatris, AbbVie - openPR.com
Gilead Sciences Stock Performance vs. Business Health Analysis 2026News and Statistics - IndexBox
Is trending stock Gilead Sciences, Inc. (GILD) a buy now? - MSN
Danske Bank A S Takes $133.05 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Captrust Financial Advisors Has $211.80 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Achmea Investment Management B.V. - MarketBeat
Gilead Sciences CFO Dickinson sells $432k in stock - Investing.com
Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 3,000 Shares - MarketBeat
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus
Gilead Sciences (NASDAQ:GILD) CFO Sells $432,690.00 in Stock - MarketBeat
Manta Cares and Gilead Sciences Announce Collaboration to Support Patients Navigating Metastatic Breast and Lung Cancer - Femtech Insider
Gilead Sciences ASCENT-04 regimen gains Category 1 status in updated NCCN guidelines - Traders Union
Manta Cares and Gilead Sciences Collaborate to Support Patients Navigating Metastatic Lung and Breast Cancer - PRWeb
Cantor Fitzgerald reiterates Gilead stock rating on Yeztugo sales - Investing.com
National Bank of Canada FI Has $161.14 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Conference: 6-Month HIV Regimens, 12-Month PrEP, Livdelzi Expansion, Oncology Push - Yahoo Finance
Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth - MarketBeat
Fort Point Capital Partners LLC Sells 8,153 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
CSM Advisors LLC Sells 42,400 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Bank of Nova Scotia Sells 319,843 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal - The Motley Fool
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal - The Motley Fool
Gotham Asset Management Increases Gilead Sciences Stake - National Today
Gilead Sciences, Inc. (NASDAQ:GILD) Short Interest Down 15.7% in February - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Holocene Advisors LP - MarketBeat
Gotham Asset Management LLC Has $38.40 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Crawford Investment Counsel Inc. Decreases Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (GILD): Growth prospects backed by analyst upgrades - MSN
Gilead Sciences, Inc. (GILD): Growth Prospects Backed by Analyst Upgrades - Insider Monkey
Capitolis Liquid Global Markets LLC Invests $40.40 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Calydon Capital Has $7.34 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Chevy Chase Trust Holdings LLC Has $70.93 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
California Public Employees Retirement System Has $447.80 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
BNP Paribas Has $7.71 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Banco Bilbao Vizcaya Argentaria S.A. Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Ameriprise Financial Inc. Buys 400,002 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Alliancebernstein L.P. Sells 258,213 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Wellington Management Group LLP Has $2.84 Billion Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Prudential PLC - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oruka Therapeutics (ORKA), Radnet (RDNT) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD) - The Globe and Mail
Dodge & Cox Trims Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Upgraded at Wall Street Zen - MarketBeat
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.99%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):